Ensysce Biosciences (ENSC) Accounts Payables (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Accounts Payables of $3.3 million for Q4 2025, up 140.78% year-over-year from $1.4 million in Q4 2024, and up 605.05% quarter-over-quarter from $463458.0 in Q3 2025.
Ensysce Biosciences (ENSC) Accounts Payables (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Accounts Payables for 9 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accounts Payables rose 140.78% year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $3.3 million (up 140.78% YoY), while the FY2025 annual figure was $3.3 million, up 140.78% from the prior year.
- Accounts Payables climbed to $3.3 million in Q4 2025 per ENSC's latest filing, from $463458.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $3.3 million in Q4 2025 and bottomed at $301104.0 in Q4 2021.
- Historically, Accounts Payables has averaged $1.4 million across 5 years, with a median of $1.2 million in 2023.
- On a YoY basis, Accounts Payables climbed as much as 1818.74% in 2021 and fell as far as 90.87% in 2021.
- Ensysce Biosciences' Accounts Payables stood at $301104.0 in 2021, then jumped by 877.67% to $2.9 million in 2022, then tumbled by 34.23% to $1.9 million in 2023, then declined by 29.9% to $1.4 million in 2024, then jumped by 140.78% to $3.3 million in 2025.
- Business Quant data shows ENSC's Accounts Payables at $3.3 million in Q4 2025, $463458.0 in Q3 2025, and $1.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | 3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.27 Mn |
| Sep 30, 2025 | 463,458.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 615,295.00 |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Jun 30, 2024 | 481,971.00 |
| Mar 31, 2024 | 981,720.00 |
| Dec 31, 2023 | 1.94 Mn |
| Sep 30, 2023 | 916,416.00 |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | 1.60 Mn |
| Dec 31, 2022 | 2.94 Mn |
| Sep 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 3.05 Mn |
| Mar 31, 2022 | 959,630.00 |
| Dec 31, 2021 | 301,104.00 |
| Sep 30, 2021 | 471,858.00 |
| Jun 30, 2021 | 3.14 Mn |
| Mar 31, 2021 | 319,180.00 |